Irinotecan, docetaxel and oxaliplatin combination in metastatic gastric or gastroesophageal junction adenocarcinoma

British Journal of Cancer

Volumn 97, Issue 5, 2007, Pages 593-597

  Di Lauro, L ^a   Nunziata, C ^b   Arena, M G ^c   Foggi, P ^a   Sperduti, I ^a   Lopez, M ^a  

^a REGINA ELENA NATIONAL CANCER INSTITUTE   (Italy)

^b San Giuseppe Hospital   (Italy)

^c Toraldo Hospital   (Italy)

Author keywords

Docetaxel; Irinotecan; Metastatic gastric cancer; Oxaliplatin

Indexed keywords

CAPECITABINE; CISPLATIN; DOCETAXEL; EPIRUBICIN; FLUOROURACIL; IRINOTECAN; OXALIPLATIN;

ADULT; AGED; ALOPECIA; ANEMIA; ARTICLE; BONE MARROW SUPPRESSION; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER SURVIVAL; CARDIOTOXICITY; CLINICAL ARTICLE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DRUG ACTIVITY; DRUG DOSE REDUCTION; DRUG FATALITY; DRUG HYPERSENSITIVITY; DRUG SAFETY; DRUG TOLERABILITY; ESOPHAGEAL ADENOCARCINOMA; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; FLUID RETENTION; HUMAN; LOWER ESOPHAGUS SPHINCTER; MALE; METASTASIS; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUROTOXICITY; NEUTROPENIA; OUTCOME ASSESSMENT; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; SIDE EFFECT; STOMACH ADENOCARCINOMA; THROMBOCYTOPENIA; TREATMENT RESPONSE; VOMITING;

ADENOCARCINOMA; ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAMPTOTHECIN; DIARRHEA; DISEASE PROGRESSION; ESOPHAGOGASTRIC JUNCTION; FEMALE; FEVER; HUMANS; KAPLAN-MEIERS ESTIMATE; MALE; MIDDLE AGED; MUCOSITIS; NEOPLASM METASTASIS; NEUTROPENIA; ORGANOPLATINUM COMPOUNDS; STOMACH NEOPLASMS; TAXOIDS; TREATMENT OUTCOME; VOMITING;

EID: 34548311988     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/sj.bjc.6603917     Document Type: Article

References (24)

1. A'Hern RP (2001) Sample size tables for exact single-stage phase II designs. Statist Med 20: 859-866
2. Ajani J (2006) Review of capecitabine as oral treatment of gastric, gastroesophageal, and esophageal cancers. Cancer 107: 221-231
3. Al-Batran SE, Atmaca A, Hegewisch-Becker S, Jaeger D, Hahnfeld S, Rummel MJ, Seipelt G, Rost A, Orth J, Knuth A, Jaeger E (2004) Phase II trial of biweekly infusional fluorouracil, folinic acid, and oxaliplatin in patients with advanced gastric cancer. J Clin Oncol 22: 658-663
4. Bleiberg H (1999) CPT-11 in gastrointestinal cancer. Eur J Cancer 35: 371-379
5. Chang HM, Kim TW, Yook JH, Oh ST, Kim WK, Lee JS, Kang JK (2003) Phase II study of irinotecan (I) and docetaxel (D) as second line chemotherapy for patients with previously treated advanced gastric cancer (AGC). Proc Am Soc Clin Oncol 22: 328 (abstract 1316)
6. Cunningham D, Rao S, Starling N, Iveson T, Nicolson M, Coxon F, Middleton G, Daniel F, Oates J, Norman AR (2006) Randomized multicentre phase III study comparing capecitabine with fluorouracil and oxaliplatin with cisplatin in patients with advanced oesophagogastric (OC) cancer: The REAL 2 trial. J Clin Oncol 24(S18): 182s (abstract LBA4017)
7. Dank M, Zaluski J, Barone C, Valvere V, Peschel C, Wenczl M, Goker E, Risse M, Award L, Bugatet R (2005) Randomized phase 3 trial of irinotecan (CPT-11)+ 5FU/folinic acid (FA) vs CDDP+5FU in 1st-line advanced gastric cancer patients. J Clin Oncol 23(S16): 308s (abstract 4003)
8. Devesa SS, Fraumeni JF (1999) The rising incidence of gastric cardia cancer. J Natl Cancer Inst 91: 747-749
9. Hawkins R, Cunningham D, Soerbye H, Adenis A, Canon JL, Lopez-Vivanco G, Jacques C, Stenger P, Zuber E, Misset JL (2003) Randomized phase II trial of docetaxel plus irinotecan vs docetaxel plus 5-fluorouracil (5FU) in patients with untreated advanced gastric adenocarcinoma (AGAC). Proc Am Soc Clin Oncol 22: 257 (abstract 1032)
10. Hundahl S, Phillips J, Menck H (2000) The national cancer data base report on poor survival of US gastric carcinoma patients treated with gastrectomy: fifth edition American joint committee on cancer staging, proximal disease, and the ' different disease' hypothesis. Cancer 88: 921-932
11. Kamangar F, Dores GM, Anderson WF (2006) Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world. J Clin Oncol 24: 2137-2150
12. Kohne CH, Thuss-Patience P, Catane R, Klein H, Peretz T, Preusser P, Niederle N, Ducreux M, Hansjokem W, Jacques C (1999) Final results of a phase II trial of CPT-11 in patients with advanced gastric cancer. Proc Am Soc Clin Oncol 18: 258 (abstract 993)
13. Louvet C, André T, Tigaud JM, Gamelin E, Douillard JY, Brunet R, Francois E, Jacob JH, Levoir D, Taamma A, Rougier P, Cvitkovic E, de Gramont A (2002) Phase II study of oxaliplatin, fluorouracil, and folinic acid in locally advanced or metastatic gastric cancer patients. J Clin Oncol 20: 4543-4548
14. Park SR, Chun JH, Yu MS, Lee JH, Ryu KW, Choi IJ, Kim CG, Lee JS, Kim YW, Bae JM, Kim HK (2006) Phase II study of docetaxel and irinotecan combination chemotherapy in metastatic gastric carcinoma. Br J Cancer 94: 1402-1406
15. Pinto C, Di Fabio F, Siena S, Cascinu S, Rojas Llimpe FL, Ceccarelli C, Mutri V, Giannetta L, Giaquinta S, Funaioli C, Berardi R, Longobardi C, Piana E, Martoni A (2007) Phase II study of cetuximab in combination with FOLFIRI in patients with untreated advanced gastric or gastroesophageal junction adenocarcinoma (FOLCETUX study). Ann Oncol 18: 510-517
16. Richards DA, Wilfong L, Reznick D, McCollum D, Boehm KA, Zhan L, Asmar L (2006) Phase II multicenter trial of docetaxel+oxaliplatin in stage IV gastroesophageal and/or stomach cancer. J Clin Oncol 24(S18): 195s (abstract 4071)
17. Rivera F, Vega-Villegas ME, Lopez-Brea MF (2007) Chemotherapy of advanced gastric cancer. Cancer Treat Rev 33: 315-324
18. Shah MA, Ramanathan RK, Ilson DH, Levnor A, D'Adamo D, O'Reilly E, Tse A, Trocola R, Schwartz L, Capanu M, Schwartz GK, Kelsen DP (2006) Multicenter phase II study of irinotecan, cisplatin, and bevacizumab in patients with metastatic gastric or gastroesophageal junction adenocarcinoma. J Clin Oncol 24: 5201-5206
19. Souglakos J, Syrigos K, Potamianou A, Polyzos A, Boukovinas I, Androulakis N, Kouroussis C, Vardakis N, Christophilakis C, Kotsakis A, Georgoulias V (2004) Combination of irinotecan (CPT-11) plus oxaliplatin (L-OHP) as first-line treatment in locally advanced or metastatic gastric cancer: a multicentre phase II trial. Ann Oncol 15: 1204-1209
20. Therasse P, Arbuck SG, Eisenhauer E, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van Oosterom AT, Christian MC, Gwyther SG (2000) New guidelines to evaluate the response to treatment in solid tumours. J Natl Cancer Inst 92: 205-216
21. Thuss-Patience PC, Kretzschmar A, Reichardt P (2006) Docetaxel in the treatment of gastric cancer. Future Oncol 2: 603-620
22. Van Cutsem E, Moiseyenko VM, Tjulandin S, Majlis A, Constenla M, Boni C, Rodigues A, Fodor M, Chao Y, Voznyi E, Risse ML, Ajani JA (2006) Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 study group. J Clin Oncol 24: 4991-4997
23. Wagner AD, Grothe W, Haerting J, Kleber G, Grothey A, Fleig WE (2006) Chemotherapy in advanced gastric cancer: a systemic review and meta-analysis based on aggregate data. J Clin Oncol 24: 2903-2909
24. Woell E, Kühr T, Eisterer W, Gattringer K, Greil R, Zabernigg A, Hilbe W, Thaler J (2006) Oxaliplatin and irinotecan chemotherapy in advanced gastric cancer. Final results of a multicenter phase II trial. J Clin Oncol 24(S18): 195s (abstract 4070)